Amedisys Inc (AMED) Rating Increased to Buy at Mizuho

Amedisys Inc (NASDAQ:AMED) was upgraded by research analysts at Mizuho from a “neutral” rating to a “buy” rating in a research report issued on Thursday.

A number of other research analysts also recently commented on the company. Royal Bank Of Canada reiterated a “hold” rating on shares of Amedisys in a research report on Monday, October 23rd. Jefferies Group LLC reiterated a “buy” rating and set a $60.00 target price on shares of Amedisys in a research report on Thursday, October 12th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $60.00 target price on shares of Amedisys in a research report on Monday, October 9th. Robert W. Baird reiterated a “hold” rating and set a $50.00 target price on shares of Amedisys in a research report on Wednesday, October 4th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $60.00 target price on shares of Amedisys in a research report on Friday, September 15th. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Amedisys currently has an average rating of “Buy” and an average price target of $56.10.

Amedisys (NASDAQ AMED) traded up $1.65 during midday trading on Thursday, hitting $54.80. The stock had a trading volume of 514,340 shares, compared to its average volume of 467,569. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.17. The company has a market cap of $1,855.64, a P/E ratio of 28.99, a P/E/G ratio of 1.34 and a beta of 0.68. Amedisys has a 52-week low of $34.58 and a 52-week high of $65.91.

TRADEMARK VIOLATION NOTICE: “Amedisys Inc (AMED) Rating Increased to Buy at Mizuho” was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/11/05/amedisys-inc-amed-rating-increased-to-buy-at-mizuho.html.

In related news, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the completion of the sale, the insider now directly owns 10,488 shares in the company, valued at $524,400. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.00% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. lifted its position in Amedisys by 1.5% in the second quarter. Victory Capital Management Inc. now owns 702,239 shares of the health services provider’s stock worth $44,108,000 after buying an additional 10,080 shares during the last quarter. UBS Asset Management Americas Inc. lifted its position in Amedisys by 23.9% in the second quarter. UBS Asset Management Americas Inc. now owns 14,572 shares of the health services provider’s stock worth $915,000 after buying an additional 2,812 shares during the last quarter. Thrivent Financial For Lutherans lifted its position in shares of Amedisys by 3.8% during the first quarter. Thrivent Financial For Lutherans now owns 15,703 shares of the health services provider’s stock worth $802,000 after purchasing an additional 570 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Amedisys by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock worth $121,067,000 after purchasing an additional 63,238 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Amedisys by 3.2% during the first quarter. Geode Capital Management LLC now owns 231,953 shares of the health services provider’s stock worth $11,850,000 after purchasing an additional 7,279 shares during the last quarter. Institutional investors own 96.86% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

What are top analysts saying about Amedisys Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amedisys Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit